LEO Pharma A/S-Product Pipeline Review-2015

LEO Pharma A/S-Product Pipeline Review-2015

  • Products Id :- GMDHC07053CDB
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

LEO Pharma A/S-Product Pipeline Review-2015


Global Markets Direct's, 'LEO Pharma A/S-Product Pipeline Review-2015', provides an overview of the LEO Pharma A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of LEO Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of LEO Pharma A/S including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of LEO Pharma A/S's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the LEO Pharma A/S's pipeline products

Reasons To Buy

Evaluate LEO Pharma A/S's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of LEO Pharma A/S in its therapy areas of focus

Identify new drug targets and therapeutic classes in the LEO Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of LEO Pharma A/S and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of LEO Pharma A/S

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of LEO Pharma A/S and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

LEO Pharma A/S Snapshot 6

LEO Pharma A/S Overview 6

Key Information 6

Key Facts 6

LEO Pharma A/S-Research and Development Overview 7

Key Therapeutic Areas 7

LEO Pharma A/S-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Combination Treatment Modalities 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

LEO Pharma A/S-Pipeline Products Glance 14

LEO Pharma A/S-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

LEO Pharma A/S-Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

LEO Pharma A/S-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

LEO Pharma A/S-Drug Profiles 19

(calcipotriene + betamethasone dipropionate) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

aprepitant 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

cromolyn sodium 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ingenol mebutate 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

LEO-43204 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

LP-0113 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

LEO-130852A 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

LEO-32731 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

LEO-39652 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

VBY-891 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

LP-0067 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecules to Antagonize MCHR1 for Weight Loss 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Activate Protein Kinase C for Dermatology and Cancer 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

LEO Pharma A/S-Pipeline Analysis 34

LEO Pharma A/S-Pipeline Products by Target 34

LEO Pharma A/S-Pipeline Products by Route of Administration 35

LEO Pharma A/S-Pipeline Products by Molecule Type 36

LEO Pharma A/S-Pipeline Products by Mechanism of Action 37

LEO Pharma A/S-Recent Pipeline Updates 38

LEO Pharma A/S-Dormant Projects 41

LEO Pharma A/S-Discontinued Pipeline Products 42

Discontinued Pipeline Product Profiles 42

(calcipotriene + hydrocortisone butyrate) 42

TD-1414 42

LEO Pharma A/S-Company Statement 43

LEO Pharma A/S-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

LEO Pharma A/S, Key Information 6

LEO Pharma A/S, Key Facts 6

LEO Pharma A/S-Pipeline by Indication, 2015 8

LEO Pharma A/S-Pipeline by Stage of Development, 2015 9

LEO Pharma A/S-Monotherapy Products in Pipeline, 2015 10

LEO Pharma A/S-Combination Treatment Modalities in Pipeline, 2015 11

LEO Pharma A/S-Partnered Products in Pipeline, 2015 12

LEO Pharma A/S-Partnered Products/ Combination Treatment Modalities, 2015 13

LEO Pharma A/S-Pre-Registration, 2015 14

LEO Pharma A/S-Phase II, 2015 15

LEO Pharma A/S-Phase I, 2015 16

LEO Pharma A/S-Preclinical, 2015 17

LEO Pharma A/S-Discovery, 2015 18

LEO Pharma A/S-Pipeline by Target, 2015 34

LEO Pharma A/S-Pipeline by Route of Administration, 2015 35

LEO Pharma A/S-Pipeline by Molecule Type, 2015 36

LEO Pharma A/S-Pipeline Products by Mechanism of Action, 2015 37

LEO Pharma A/S-Recent Pipeline Updates, 2015 38

LEO Pharma A/S-Dormant Developmental Projects,2015 41

LEO Pharma A/S-Discontinued Pipeline Products, 2015 42

LEO Pharma A/S, Other Locations 44

LEO Pharma A/S, Subsidiaries 45

List of Figures

LEO Pharma A/S-Pipeline by Top 10 Indication, 2015 8

LEO Pharma A/S-Pipeline by Stage of Development, 2015 9

LEO Pharma A/S-Monotherapy Products in Pipeline, 2015 10

LEO Pharma A/S-Partnered Products in Pipeline, 2015 12

LEO Pharma A/S-Pipeline by Top 10 Target, 2015 34

LEO Pharma A/S-Pipeline by Top 10 Route of Administration, 2015 35

LEO Pharma A/S-Pipeline by Top 10 Molecule Type, 2015 36

LEO Pharma A/S-Pipeline Products by Top 10 Mechanism of Action, 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com

Current R&D Portfolio of LEO Pharma A/S; LEO Pharma A/S - Key Therapeutics; LEO Pharma A/S - Pipeline Overview and Promising Molecules; LEO Pharma A/S - News; LEO Pharma A/S - Latest Updates; LEO Pharma A/S - Pipeline; LEO Pharma A/S - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 96585
Site License
USD 3000 INR 193170
Corporate User License
USD 4500 INR 289755



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@] kenresearch.com